MAPRx strongly supports CMS’ proposal to permit coverage of anti-obesity medications to treat obesity for appropriate indications. AOMs are a critical component of the continuum of obesity care. Read our Comment Letter
MAPx appreciates the opportunity to comment on specific provisions in the CY 2026 policy and technical changes to MA and Part D. Read the Comment Letter
The IRA enacted the most significant changes to Part D since its inception, and these reforms have major implications for Medicare beneficiaries. In this new paper, the MAPRx Coalition examines the potential impact of three of IRA’s major Part D…
The MAPRx Coalition (MAPRx) appreciates the opportunity to provide the Centers for Medicare & Medicaid Services (CMS) with comments regarding the new model documents for the implementation of the Medicare Prescription Payment Plan (MPPP) program set to take effect for…
The MAPRx Coalition is pleased that CMS has made several important changes to the Part D Reporting Requirements, many of which the Coalition advocated for in our April 2 comments. READ FULL COMMENTS HERE
The MAPRx Coalition appreciates the opportunity to provide the Centers for Medicare & Medicaid Services (CMS) with comments regarding Medicare Part D plan sponsor data reporting requirements, as requested in the notice published in the Federal Register on February 2,…
MAPRx urges Congress and CMS to establish comprehensive obesity coverage in Medicare Part D through a one pager. Highlights include: • Treat and Reduce Obesity Act: Bipartisan, bicameral legislation to establish anti-obesity medication coverage through Medicare Part D• CMS Guidance:…
Earlier today the MAPRx Coalition submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the memorandum Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for…